Mylan sued over alleged EpiPen exclusivity rebates

Sanofi sued EpiPen maker Mylan on Monday for allegedly suppressing competition in the market for drugs used to treat severe allergic reactions, by creating a rebate program for third party payors specifically conditioned on payors exclusively purchasing EpiPen.

Unlock unlimited access to all Global Competition Review content